Lasa Supergenerics Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Lasa Supergenerics Ltd indicates a cautious stance for investors, signalling significant risks and challenges facing the company. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s investment potential and risk profile.

Quality Assessment

As of 02 July 2026, Lasa Supergenerics’ quality grade is categorised as below average. The company has been grappling with operational difficulties, reflected in its weak long-term fundamental strength. Operating losses persist, and the ability to service debt remains poor, with an average EBIT to interest ratio of -5.16. This negative ratio highlights the company’s struggle to generate sufficient earnings before interest and taxes to cover its interest expenses, raising concerns about financial stability.

Additionally, the return on equity (ROE) stands at a modest 3.54%, indicating low profitability relative to shareholders’ funds. This level of ROE suggests that the company is not efficiently generating returns for its investors, which is a critical consideration for long-term shareholders.

Valuation Perspective

The valuation grade for Lasa Supergenerics is currently deemed risky. The company’s financial results have deteriorated significantly, with negative EBITDA of ₹-7.36 crores reported recently. This negative earnings before interest, taxes, depreciation, and amortisation figure signals operational inefficiencies and cash flow challenges.

Moreover, the stock’s price performance has been weak, with a one-year return of -36.85% as of 02 July 2026. This underperformance is compounded by a drastic fall in profits, which have declined by approximately 975.8% over the past year. Such steep declines in profitability and returns suggest that the stock is trading at valuations that reflect elevated risk, making it less attractive from a value investing standpoint.

Financial Trend Analysis

The financial trend for Lasa Supergenerics is classified as negative. The company has reported losses for three consecutive quarters, underscoring ongoing operational challenges. Net sales for the nine-month period stand at ₹5.13 crores, representing a sharp contraction of 95.40% compared to previous periods. This significant decline in revenue is a red flag for investors, indicating shrinking market demand or operational setbacks.

Profit before tax (PBT) excluding other income has plummeted to ₹-3.56 crores, a fall of 493.33%, while the net profit after tax (PAT) for the quarter is ₹-3.70 crores, down 138.5%. These figures highlight the company’s inability to generate profits and maintain financial health, which is a critical factor in the current rating.

Technical Outlook

From a technical perspective, the stock is rated as mildly bearish. Price movements over recent periods show volatility and downward pressure. The stock’s short-term returns include a 1-month decline of 5.56% and a 6-month drop of 35.57%. Although there was a 16.80% gain over the past three months, this was insufficient to offset the broader negative trend.

Year-to-date, the stock has declined by 22.09%, and the one-year return of -36.85% reflects consistent underperformance relative to the broader market benchmarks such as the BSE500. This technical weakness supports the cautious stance reflected in the Strong Sell rating.

Performance Relative to Benchmarks

Lasa Supergenerics has consistently underperformed the BSE500 index over the last three years. This persistent lag in returns, combined with deteriorating financial metrics, reinforces the rationale behind the current rating. Investors should be aware that the stock’s risk profile remains elevated, and the company faces significant headwinds in returning to profitability and growth.

What This Rating Means for Investors

The Strong Sell rating on Lasa Supergenerics Ltd serves as a clear caution to investors. It suggests that the stock currently carries a high degree of risk due to weak financial health, poor operational performance, and unfavourable market sentiment. Investors should carefully consider these factors before initiating or maintaining positions in the stock.

For those holding the stock, the rating implies a need for vigilance and possibly re-evaluating their exposure, given the company’s ongoing losses and negative trends. Prospective investors may want to await signs of financial recovery, improved profitability, and stabilisation in technical indicators before considering entry.

In summary, the combination of below-average quality, risky valuation, negative financial trends, and mildly bearish technicals underpin the Strong Sell rating. This comprehensive assessment provides a holistic view of the stock’s challenges and guides investors in making informed decisions aligned with their risk tolerance and investment objectives.

Company Profile and Market Context

Lasa Supergenerics Ltd operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap company. The sector itself is known for its volatility and sensitivity to regulatory and market developments. Given the company’s current financial and operational difficulties, it faces an uphill task to regain investor confidence and improve its market standing.

The Mojo Score of 9.0, down from 33 previously, reflects the significant deterioration in the company’s overall health and outlook. This score is a quantitative measure that integrates various fundamental and technical factors, reinforcing the Strong Sell recommendation.

Stock Price and Returns Overview

As of 02 July 2026, the stock price has remained flat on the day with a 0.00% change, but the broader trend remains negative. The stock’s returns over multiple time frames illustrate the volatility and challenges faced:

• 1 Day: +0.00%
• 1 Week: -1.62%
• 1 Month: -5.56%
• 3 Months: +16.80%
• 6 Months: -35.57%
• Year-to-Date: -22.09%
• 1 Year: -36.85%

These figures highlight the stock’s inconsistent performance and overall downward trajectory, which investors should factor into their decision-making process.

Conclusion

In conclusion, Lasa Supergenerics Ltd’s Strong Sell rating by MarketsMOJO, last updated on 11 Feb 2025, remains justified based on the company’s current financial and operational realities as of 02 July 2026. The combination of weak quality metrics, risky valuation, negative financial trends, and bearish technical signals presents a challenging outlook for the stock. Investors are advised to approach this stock with caution and closely monitor any developments that could signal a turnaround.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →